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Session: Disease & Treatment 89chondrocytes. Rebamipide down-regulated the mRNA expression of IL-1b, TNF, and
NF-kB, thus Rebamipide had an anti-inflammatory effect in chondrocytes. Rebami-
pide down-regulated catabolic factors (MMP3, MMP13, and ADAMTS5) in chondro-
cytes. Injection of Rebamipide could prevent articular cartilage degeneration for
six weeks. These findings indicate that intra-articular injection of Rebamipide pre-
vents matrix breakdown and the development of OA. In conclusion, intra-articular
injection of Rebamipide prevented articular cartilage degeneration for six weeks
in murine models of osteoarthritis, Rebamipide down-regulated catabolic factors,
and up-regulated anabolic factors in human chondrocytes. Rebamipide could be
an important candidate for prevention of articular cartilage degeneration.
http://dx.doi.org/10.1016/j.jot.2016.06.06464
STRUCTURAL SIMULATION OF ADENOSINE PHOSPHATE VIA PLUMBAGIN AND
ZOLEDRONIC ACID COMPETITIVELY TARGETS JNK/Erk TO SYNERGISTICALLY
ATTENUATE OSTEOCLASTOGENESIS IN A BREAST CANCER MODEL
Han Qiao, Tingting Tang
Shanghai Ninth Hospital, China
Objective: The treatment of breast cancer and subsequent osteolysis remains a
challenge in clinical settings. The aim of this study was to explore the effect
and mechanism of combined treatment with zoledronic acid (ZA) and plumbagin
(PL), a widely investigated component derived from Plumbago Zeylanica, against
breast cancer and cancer-induced osteoclastogenesis.
Methods: Quantitative synergism was evaluated using Compusyn software with
determined combination index (CI) and drug reduction index (DRI) values. The
attenuated malignancies after dual-drug treatment against breast cancer cells
were evaluated with a CCK-8 assay, flow cytometry, and a transwell assay. The
cancer-associated osteoclast formation in vitro after stimulation of receptor acti-
vator for nuclear factor-kB ligand (RANKL) or conditioned medium from MDA-MB-
231 human breast cancer cells upon murine bone marrow-derived monocytes
(BMMs) and human peripheral blood mononucleated cells (hPBMCs), respectively,
were assessed with tartrate-resistant acid phosphatase (TRAcP) staining. Western
blot, real-time PCR, homogeneous time-resolved fluorescence (HTRF) assay, and
molecular docking were used to unravel the underlying synergistic anti-tumorigen-
esis and anti-osteoclastogenesis mechanisms. Non-invasive imaging system (IVIS),
mCT scanning, and immunohistochemistrical analysis were deployed to investigate
the anti-tumorigenesis and anti-osteoclastogenesis effects in vivo after dual-drug
treatment in an intra-tibiae breast cancer model.
Results: We found that the combination of PL and ZA triggered cytotoxicity
(CIZ0.26), induced apoptosis, and inhibited migration of breast cancer cells syner-
gistically. When the breast cancer cells were transfected with specific siRNA against
Notch-1, the combination of ZA and PL markedly increased the expression of Bcl-2.
Combined treatment also suppressed cell viability of precursor osteoclasts and syn-
ergistically inhibited MDA-MB-231 induced osteoclast formation (CIZ0.28) with the
abrogation of RANKL-induced activation of NF-kB/MAPK pathways. Molecular dock-
ing suggested a putative binding area within JNK/Erk protease active sites through
structural mimicking of adenosine phosphate (ANP) by the spatial combination of
PL with ZA. A HTRF assay further illustrated the direct competitiveness of the
dual drugs against ANP docking to phosphorylated JNK/Erk, contributing to the
inhibited downstream expression of c-Jun/c-Fos/NFATc-1. Then, in vivo testing
demonstrated that the combined administration of PL and ZA attenuated breast
cancer growth in the bone microenvironment. Additionally, these molecules pre-
vented the destruction of the proximal tibia, with significant reduction of TRAcP
positive osteoclast cells and potentiation of apoptotic cancer cells, to a greater
extent when combined than when the drugs were applied independently.
Conclusion: The combination treatment with PL and ZA could significantly and
synergistically inhibit tumorigenesis and suppress osteoclastogenesis both in vitro
and in vivo by modulating Notch-1-Bcl-2 signalling and simulating the spatial struc-
ture of adenosine phosphate to competitively inhibit phosphorylation of JNK/Erk.
http://dx.doi.org/10.1016/j.jot.2016.06.06567
TENASCIN-C PROMOTES THE REPAIR OF FULL-THICKNESS OSTEOCHONDRAL
DEFECTS IN MICE
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Japan
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Introduction: Tenascin-C (TNC) is an extracellular matrix glycoprotein. While the
expression is repressed in normal adult tissues, it reappears under pathological
conditions such as wound healing, regeneration, and tumorigenesis. In articular
cartilage, TNC expression is associated with development and is almost absent inadult cartilage. In diseased joints, including those with osteoarthritis (OA), TNC
was highly recurring in cartilage. Our previous studies have demonstrated that
full-length TNC promoted chondrocyte proliferation and increased proteoglycan
content in vitro, and promoted the repair of full-thickness osteochondral defects
in rabbits. In this study, we examined the effects of full-length TNC on joint carti-
lage repair and on synovial inflammation in full-thickness osteochondral defects
model mice. In addition, we performed an in vitro study to reveal the mechanism
of repairing cartilage using full-length TNC.
Methods: Full-length TNC was purified from culture supernatant of human glioma
cells U-251 MG. Male 8-week-old BALB/c strain mice were used. In vivo study: Full-
thickness osteochondral defects were created in the centre of the femoral
trochlea with a hand micro-drill equipped with a 0.3-mm diameter drill-bit. The
defect was filled with TNC (group A: 100mg/ml, group B: 10mg/ml, group C: empty)
by direct administration. Mice were sacrificed at 1, 2, 3, and 6 weeks postopera-
tively (nZ10 knees in each groups at every time point), and whole knee joints
were removed by dissection. Histological examinations were made using haema-
toxylin & eosin (H-E) and Safranin-O (Saf-O) staining. Cartilage repair was evalu-
ated using the modified WAKITANI score. Synovitis was evaluated using synovitis
score according to Krenn. In vitro study: Human cartilage specimens were obtained
from patients who underwent total knee arthroplasty for the treatment of OA.
Chondrocytes were isolated and cultured and they were treated with 0mg/ml,
1mg/ml, or 10mg/ml of TNC. We compared the expression of numerous kinds of
mRNA for every dose by real-time PCR. We evaluated the expression of TNC, in-
flammatory cytokines [TNF-a, IL-1b], anabolic factors [TGFb, TIMP3, bFGF], and
catabolic factors [ADAMTS4, 5, and MMP3, 13].
Results: In vivo study: In Saf-O-staining, the defects in Group A were covered with
hyaline-like cartilage at 3 and 6 weeks. Average modified WAKITANI scores were
significantly better in group A than group B and C at 3 and 6 weeks [3weeks: group
A: 6.2, group B: 7.8, group C: 9.8 (p<0.05); 6weeks: group A: 6.4, group B: 7.6,
group C: 8.6 (p<0.05)]. At 1 and 2 weeks, there was no significant difference in
the average scores in all groups. Low-grade synovitis occurred in both groups at
each week. There were no significant differences in average synovitis scores be-
tween the two groups at each day. In vitro study: Both 1mg/ml and 10mg/ml of
TNC up-regulated the expression of TNFa and IL-1b. 10mg/ml TNC up-regulated
the expression of endogenous TNC, TGFb, TIMP3 and ADAMTS4, MMP3, MMP13,
but 10mg/ml of TNC down-regulated the expression of ADAMTS5.
Conclusion: This study demonstrated that full-thickness osteochondral defects in
mice with 100mg/ml of TNC were successfully repaired with hyaline-like cartilage
without exacerbating synovitis. The in vitro study demonstrated that TNC up-reg-
ulates itself and anabolic factors. TNC up-regulated the expression of ADAMTS4,
but down-regulated the expression of ADAMTS5, which contributed to cartilage
degradation. We consider that TNC could repair the cartilage using these
mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.06675
ADVANCED MUSCULOSKELETAL IMAGING SYSTEMS ADOPTED FOR STUDYING A
NOVEL BONE-TARGETING DELIVERY SYSTEM CARRYING OSTEOPROMOTIVE
PHYTOMOLECULE(S) DEVELOPED FOR THE PREVENTION OF OESTROGEN
DEPLETION-INDUCED OSTEOPOROSIS
Le Huang
The Chinese University of Hong Kong, Hong Kong SAR, China
Introduction: Epimedium is a usual herb used in herbal Fufang (formula) in TCM to
strengthen bone and Icaritin is the most potential metabolite of Epimedium. This
study was designed to develop an Icaritin-containing bone targeting delivery sys-
tem for evaluation of its prevention effects on estrogen-depletion induced osteo-
porosis in experimental model.
Subjects and Methods: To evaluate the efficacy of Icaritin with targeting liposome
delivery system on prevention of osteoporosis in vivo by analyzing the bone quality
and microarchitecture by micro-computed tomography (micro-CT) and the organ
distribution of the delivery system by using Xenogen IVIS spectrum system. (DSS6)-
liposome-Icaritin was firstly synthesized by thin film evaporation method with
extruding through polycarbonate filter membranes to obtain unilamellar vesicles.
Then the bone targeting molecules DSS6 were attached to the surface of the
vesicles. Eighty 4-month-old C57/BL6 female mice were divided into 9 groups
(nZ10), including Baseline (BL), Sham surgery (SH), Ovariectomized only (OVX),
Estradiol for oral administration (O-E2), Icaritin for oral administration (O-ICT),
low dose (8 mg/kg, 1/week) targeting liposome delivery system with Icaritin
injected via caudal vein (IV-LIP+ICT+DSS6-L), high dose (8 mg/kg, 2/week) targeting
liposome delivery systemwith Icaritin injected via caudal vein (IV-LIP+ICT+DSS6-H),
liposome delivery systemwith Icaritin injected via caudal vein (IV-LIP+ICT, 8 mg/kg,
2/week). Except in the BL and SH groups, ovariectomy surgery (OVX) was performed
on other mice. Administration of gavage and IV injection were applied respectively
from the day right after the surgery and lasted for 6weeks. All micewere sacrificed 6
weeks after surgery. Lumbar spine and the lower limbswere harvest for bone quality
analysis. Proximal tibia was scanned by micro-CT (Scanco micro-CT 40). Trabecular
bone was identified and the parameters including bone mineral density (BMD),
